SCHEMBL418763

SCHEMBL418763

Nc1ncc2c(n1)CNC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
POLB P06746 2/20 0.37
KDM4E B2RXH2 2/20 0.37
HTR2C P28335 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.34
PARP16 Q8N5Y8 1/20 0.34
PARP3 Q9Y6F1 1/20 0.34
HSP90AA1 P07900 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
PDGFRB P09619 1/20 0.33
DRD3 P35462 2/20 0.33
CYP2D6 P10635 1/20 0.33
DRD2 P14416 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PIKFYVE Q9Y2I7 1/20 0.32
PIK3R1 P27986 1/20 0.32
PIK3CA P42336 1/20 0.32
MAPT P10636 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12497623 0.82 HTR2C (0.55) ALDH1A1POLBKDM4EHTR2CSMN1; SMN2
SCHEMBL2449506 0.82 POLB (0.51) ALDH1A1POLBKDM4EHTR2CSMN1; SMN2
SCHEMBL30648742 0.82 HTR2C (0.55) ALDH1A1POLBKDM4EHTR2CSMN1; SMN2
Hydrochloric Acid SCHEMBL31066377 0.81 POLB (0.50) ALDH1A1POLBKDM4EHTR2CSMN1; SMN2
Hydrochloric Acid SCHEMBL14763678 0.81 POLB (0.50) ALDH1A1POLBKDM4EHTR2CSMN1; SMN2
SCHEMBL1528492 0.75 HTR2C (0.37) POLBHTR2CSMN1; SMN2HSP90AA1
SCHEMBL18818489 0.75 HTR2C (0.37) POLBKDM4EHTR2CSMN1; SMN2
Hydrochloric Acid SCHEMBL2874635 0.73 HTR2C (0.36) POLBHTR2CSMN1; SMN2HSP90AA1
Hydrochloric Acid SCHEMBL21591718 0.73 HTR2C (0.36) POLBKDM4EHTR2CSMN1; SMN2
SCHEMBL30333512 0.72 HTR2C (0.33) POLBHTR2CSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018118829-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-06-28 WO disclosed
EP-2820017-B1 PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES GENENTECH INC (US) 2016-12-21 EP disclosed
US-20160355514-A1 PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES VALO EARLY DISCOVERY, INC. 2016-12-08 US disclosed
US-9458172-B2 Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives VALO HEALTH, INC. 2016-10-04 US disclosed
US-20150175621-A1 PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES Valo Health, LLC 2015-06-25 US disclosed
CN-104507936-A Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives FORMA TM LLC 2015-04-08 CN disclosed
EP-2820017-A1 PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES Genentech, Inc. (US) 2015-01-07 EP disclosed
EP-2424532-B1 COMPOUNDS FOR INDUCING CELLULAR APOPTOSIS QUEEN MARY & WESTFIELD COLLEGE (GB) 2014-09-24 EP disclosed
WO-2013127267-A1 PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES GENENTECH, INC. (US) 2013-09-06 WO disclosed
EP-2408762-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI (FR) 2012-01-25 EP disclosed
US-20120010241-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI (FR) 2012-01-12 US disclosed
WO-2011027081-A2 NOVEL DERIVATIVES OF 5,6,7,8-TETRAHYDROINDOLIZINE INHIBITING HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF SANOFI-AVENTIS (FR) 2011-03-10 WO disclosed
WO-2011004132-A1 NOVEL HSP90-INHIBITING INDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAID DERIVATIVES, AND USE THEREOF SANOFI-AVENTIS (FR) 2011-01-13 WO disclosed
WO-2010106290-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF SANOFI-AVENTIS (FR) 2010-09-23 WO disclosed
WO-2008149163-A2 POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF LECTUS THERAPEUTICS LIMITED (GB) 2008-12-11 WO disclosed
WO-2008096218-A1 2-AMIN0-5, 7-DIHYDR0-6H- PYRROLO [3, 4-D] PYRIMIDINE DERIVATIVES AS HSP-90 INHIBITORS FOR TREATING CANCER PFIZER INC. (US) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010241-A1 HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF HSP90AB2P, HSP90AB1, HSP90AA1 ALDH1A1 2177/4885POLB 3421/4885KDM4E 4500/4885
US-20160355514-A1 PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES TPMT, TYMS, TYMP ALDH1A1 1332/4885POLB 752/4885KDM4E 2902/4885
US-20150175621-A1 PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES TPMT, TYMS, TYMP ALDH1A1 1332/4885POLB 752/4885KDM4E 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.